

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 11669.147USUI	Application Number: 10/044,896
			Applicant: Chuntharapai et al.	
			Filing Date: January 9, 2002	Group Art Unit: 1644

USPTO APR 01 2005

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
YPL	4,289,690	09-15-1981	Pestka		/	
YPL	4,341,761	07-27-1982	Ganfield		/	
YPL	4,423,147	12-27-1983	Secher			
YPL	4,474,754	10-02-1984	Shimizu			
YPL	4,514,507	04-30-1985	Secher			
YPL	4,824,432	04-25-1989	Skurkovich			
YPL	4,973,556	11-27-1990	Bove			
YPL	5,055,289	10-08-1991	Frincke			
YPL	5,073,491	12-17-1991	Familletti			
YPL	5,196,323	03-23-1993	Bodo			
YPL	5,240,864	08-31-1993	Koga			
YPL	5,317,089	05-31-1994	Adolf			
YPL	5,503,828	04-02-1996	Testa			
YPL	5,516,515	05-14-1996	Vellucci			
YPL	5,626,843	05-06-1997	Skurkovich			
YPL	5,676,942	10-14-1997	Testa			
YPL	5,780,027	07-14-1998	Maroun			
YPL	5,789,551	08-04-1998	Pestka			
YPL	5,869,293	02-09-1999	Pestka			
YPL	5,888,511	03-30-1999	Skurkovich			
YPL	5,919,453	07-06-1999	Benoit			
YPL	6,001,589	12-14-1999	Pestka			
YPL	6,117,423	09-12-2000	Berg			
YPL	6,136,309	10-24-2000	Novick			
YPL	6,150,503	11-21-2000	Pestka			
YPL	2001/0012514	08-09-2001	Skurkovich			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(Use several sheets if necessary)</small>			
		Docket Number: 11669.147USUI	Application Number: 10/044,896
		Applicant: Chunthrapai et al.	
		Filing Date: January 9, 2002	Group Art Unit: 1644

APR 01 2005
CIPE RECD

<i>✓</i>	6,299,870	10-09-2001	Pestka				
<i>✓</i>	6,300,474	10-09-2001	Pestka				
<i>✓</i>	6,312,924	11-06-2001	Presnell				
<i>✓</i>	6,333,032	12-25-2001	Skurkovich				
<i>✓</i>	6,410,697	06-25-2002	Berg				
<i>✓</i>	6,433,145	08-13-2002	Lafleur				
<i>✓</i>	2002/0192748	12-19-2002	Rastelli				
<i>✓</i>	6,514,753	02-04-2003	Pestka				
<i>✓</i>	2003/0044410	03-06-2003	Skurkovich				
<i>✓</i>	6,548,056	04-15-2003	Presnell				
	2003/0138404	07-24-2003	Maroun				
	2003/0147581	08-07-2003	Doi				X
	2003/0147889	08-07-2003	Tovey				
	2004/0067888	04-08-2004	Tovey				
<i>✓</i>	2004/0105841	06-03-2004	Pestka				
<i>✓</i>	6,747,131	06-08-2004	Pestka				
<i>✓</i>	2004/0110715	06-10-2004	Escary				
<i>✓</i>	2004/0126799	07-01-2004	Escary				
<i>✓</i>	2004/0132139	07-08-2004	Escary				
<i>✓</i>	2004/0142431	07-22-2004	Escary				
<i>✓</i>	2004/0203118	10-14-2004	Escary				
<i>✓</i>	6,827,934	12-07-2004	Co et al.				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>✓</i>	CA 1306961	9-1-92	Canada				
<i>✓</i>	DD 231007	12-18-85	East Germany			Abstract Only	
<i>✓</i>	DD 254593	3-2-88	East Germany			Abstract Only	

EXAMINER	<i>Cpt</i>	DATE CONSIDERED	<i>5/11/05</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 11669.147USU1	Application Number: 10/044,896
			Applicant: Chuntharapai et al.	
			Filing Date: January 9, 2002	Group Art Unit: 1644

OPIE APR 01 2005

<i>CPK</i>	DD 265291	3-1-89	East Germany				Abstract Only	
	DD 277087	3-21-90	East Germany				Abstract Only	
	DD 279266	5-30-90	East Germany				Abstract Only	
	DD 279317	5-30-90	East Germany				Abstract Only	
	DD 279546	6-6-90	East Germany				Abstract Only	
	DD 279547	6-6-90	East Germany				Abstract Only	
	DD 279548	6-6-90	East Germany				Abstract Only	
<i>CPK</i>	DD 283154	10-3-90	East Germany				Abstract Only	
<i>CPK</i>	EP 0 050 129	3-18-92	Europe					
<i>CPK</i>	EP 0 064 063	9-11-85	Europe					
<i>CPK</i>	EP 0 091 543	10-19-83	Europe					
<i>CPK</i>	EP 0 119 476	2-16-84	Europe				Abstract Only	
<i>CPK</i>	EP 0 158 420	11-7-90	Europe					
<i>CPK</i>	EP 0 332 084		Europe					
<i>CPK</i>	EP 0 431 950	6-12-91	Europe					
<i>CPK</i>	EP 1 236 800	9-4-02	Europe					
<i>CPK</i>	FR 2657881	8-9-91	France				Abstract Only	
<i>CPK</i>	DE 4216200	11-18-93	Germany				Abstract Only	
	GB 2111527	7-6-83	United Kingdom					
	GB 2160544	12-24-85	United Kingdom					
	JP 4077431	3-11-92	Japan				Abstract Only	
	JP 58035122	3-1-83	Japan				Abstract Only	
	JP 58035124	3-1-83	Japan				Abstract Only	
	JP 58225028	12-27-83	Japan				Abstract Only	
<i>CPK</i>	JP 60065000	4-13-85	Japan				Abstract Only	

EXAMINER	<i>CPK</i>	DATE CONSIDERED	<i>5/4/05</i>
----------	------------	-----------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 11669.147USUI	Application Number: 10/044,896
			Applicant: Chunthrapai et al.	
			Filing Date: January 9, 2002	Group Art Unit: 1644

APR 01 2005

<i>CH</i>	JP 60065000	4-13-85	Japan			Abstract Only	
	JP 6050971	2-25-94	Japan			Abstract Only	
	JP 61072722	4-14-86	Japan			Abstract Only	
	JP 61099828	5-17-86	Japan			Abstract Only	
	JP 61225136	10-6-86	Japan			Abstract Only	
	JP 63142000	6-14-88	Japan			Abstract Only	
	KR 8801757	9-12-88	Korea			Abstract Only	
	KR 9200051	1-6-92	Korea			Abstract Only	
<i>CH</i>	SU 1756349	8-23-92	Soviet Union			Abstract Only	
<i>CH</i>	WO 82/01773	5-27-82	PCT				
<i>CH</i>	WO 83/00693	3-3-83	PCT				
	WO 93/20187	10-14-93	PCT				
	WO 95/13539	5-18-95	PCT			Abstract Only	
	WO 98/06431	2-19-98	PCT				
	WO 98/28001	7-2-98	PCT				
	WO 99/64440	12-16-99	PCT				
	WO 00/32223	6-8-00	PCT				
	WO 01/54721	8-2-01	PCT				
<i>CH</i>	WO 01/62287	8-30-01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>CH</i>		On Line Catalog Data Sheet for Anti-Interferon Alpha Antibodies available from Research Diagnostics, Rev. March 8, 2001, http://www.researchd.com/cytokines/ifnachrt.htm (Printed February 10, 2004)
		Antalis et al. 1998. The serine protease inhibitor (Serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon α/β priming. <i>J. Exp. Med.</i> 187: 1799-1811.
		Blanco et al. 2001. Induction of dendritic cell differentiation by IFN- α in systemic lupus erythematosus. <i>Science</i> . 294: 1540-1543.
<i>CH</i>		Cai & Garen, 1996. A melanoma-specific V _H antibody cloned from a fusion phage library of a vaccinated melanoma patient. <i>Proc. Natl. Acad. Sci. USA</i> . 93: 6280-6285.

EXAMINER	<i>CH</i>	DATE CONSIDERED	<i>5/4/05</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 11669.147USU1	Application Number: 10/044,896
		Applicant: Chuntharapai et al.	
		Filing Date: January 9, 2002	Group Art Unit: 1644

APR 8 1 2005
PTO-1449

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>YK</i>	Colamonici et al. 1993. Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21. <i>J. Biol. Chem.</i> 268: 10895-10899.
<i>YK</i>	Dansky-Ullmann et al. 1995. Synergistic effects of IL-6 and IFN- γ on carcinembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN- β . <i>Cytokine</i> . 7: 118-129.
<i>YK</i>	Desmyter et al. 2002. Three camelid VHH domains in complex with procine pancreatic α -amylase. <i>J. Biol. Chem.</i> 277: 23645-23650.
<i>YK</i>	Dhib-Jalbut et al. 1993. Direct evidence that interferon- β mediates enhanced HLA-class I expression in measles virus-infected cells. <i>J. Immunol.</i> 151: 6248-6252.
<i>YK</i>	Edge et al. 1983. Chemical synthesis of a human interferon- α_5 gene and its expression in <i>Escherichia coli</i> . <i>Nucleic Acids Res.</i> 11: 6419-6435.
<i>YK</i>	Kobiler et al., "Production of Monoclonal Antibodies Toward Bovine Interferons- α Suitable for Immunopurification", <i>J. Interferon Res.</i> , 9(2):189-193 (1989).
<i>YK</i>	Liu et al., "High-Yield Expression and Purification of Human Interferon α -1 in <i>Pichia pastoris</i> ", <i>Protein Exp. Purif.</i> , 22(3):381-387 (2001).
<i>YK</i>	Meager et al., "Development of Interferon-Specific Monoclonal Antibody for <i>In Vitro</i> Interferon Assays", <i>Dev. Biol. Stand.</i> , 64:237-248 (1986).
<i>YK</i>	Noraz et al. 1997. Human cytomegalovirus-associated immunosuppression is mediated through interferon- α . <i>Blood</i> . 89: 2443-2452.
<i>YK</i>	Slocombe et al. 1982. High-level expression of an interferon α 2 gene cloned in phage M13mp7 and subsequent purification with a monoclonal antibody. <i>Proc. Natl. Acad. Sci. USA</i> . 79: 5455-5459.
<i>YK</i>	Staehelin et al. 1981. Purification and characterization of recombinant human leukocyte interferon (IFLR α) with monoclonal antibodies. <i>J. Biol. Chem.</i> 256: 9750-9754.
<i>YK</i>	Subauste et al. 1998. Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen. <i>J. Immunol.</i> 160: 1831-1840.
<i>YK</i>	Taylor-Papadimitriou, "Epitopes of Human Interferon- α Defined by the Reaction of Monoclonal Antibodies with α Interferons and Interferon Analogs", <i>J. Immunol.</i> , 139(10):3375-3381 (1987).
<i>YK</i>	Vaughan et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", <i>Nature Biotechnology</i> , 14:309- (1996)
<i>YK</i>	Veenstra et al. 2002. IL-12 induces monocyte IL-18 binding protein expression via IFN- γ . <i>J. Immunol.</i> 168: 2282-2287.
<i>YK</i>	Visconti et al. 1999. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN- α by monoclonal antibodies. <i>J. Interferon Cytokine Res.</i> 19: 319-326.
<i>YK</i>	Zella et al. 2000. IFN- α 2b reduces IL-2 production and IL-2 receptor function in primary CD4 $^+$ T cells. <i>J. Immunol.</i> 164: 2296-2302.

EXAMINER	DATE CONSIDERED
<i>YK</i>	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 11669.147USU1	Application Number: 10/044,896
		Applicant: Chuntharapai et al.	
		Filing Date: January 9, 2002	Group Art Unit: 1644
		Zoon et al. 1992. Purification and characterization of multiple components of human lymphoblastoid Intereron- α . <i>J. Biol. Chem.</i> 267: 15210-15216.	

23552

PATENT TRADEMARK OFFICE

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>5/1/05</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			